Fresh out of the bluebird bio oncology split, Joanne Smith-Farrell flies the coop to Be Bio and its B cell platform
Stung by setbacks and a stagnant pipeline, bluebird bio, the once-darling of gene therapy biotech, made the tough call to sever its rare disease and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
